TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
Shitalkumar P Zambad, Davinder Tuli, Anoop Mathur, Sameer A Ghalsasi, Anita R Chaudhary, Shailesh Deshpande, Ramesh C Gupta, Vijay Chauthaiwale, Chaitanya DuttTorrent Research Centre, Torrent Pharmaceuticals Ltd, Gujarat, IndiaBackground: Patients with diabesity have a significantly increa...
Main Authors: | Zambad SP, Tuli D, Mathur A, Ghalsasi SA, Chaudhary AR, Deshpande S, Gupta RC, Chauthaiwale V, Dutt C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-12-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Online Access: | http://www.dovepress.com/trc210258-a-novel-tgr5-agonist-reduces-glycemic-and-dyslipidemic-cardi-a15350 |
Similar Items
-
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
by: Gupta R, et al.
Published: (2014-01-01) -
Study design and recruitment for a prospective controlled study of diabesity: Taiwan Diabesity Study
by: Wei-Jei Lee, et al.
Published: (2019-01-01) -
Diabesity in the Era of the Hapo Study
by: Juan Acosta Diez
Published: (2017-01-01) -
An Integrated View: Neuroadipocrinology of Diabesity
by: Chaldakov George N., et al.
Published: (2014-06-01) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
by: Shitalkumar P Zambad, et al.
Published: (2011-01-01)